- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to our latest study, the global Meningococcal Disease Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Meningococcal disease vaccination is a biological material given to prevent meningitis, a contagious disease of the membranes surrounding the spinal cord and brain. Conjugate, polysaccharide, and subcapsular meningococcal vaccines are the three main types of meningococcal vaccinations. They target meningococcal bacteria A, B, C, W-135, and Y and are given to new-borns, children, and adults to immunize them against the invasive disease. Antibodies are generated after the vaccination is given to combat the bacteria and develop an immune response to prevent infection.
This report is a detailed and comprehensive analysis for global Meningococcal Disease Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Meningococcal Disease Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Meningococcal Disease Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Meningococcal Disease Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Meningococcal Disease Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Meningococcal Disease Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Meningococcal Disease Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Johnson & Johnson, Mylan N.V, Teva Pharmaceutical Industries Ltd and Pfizer Inc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Meningococcal Disease Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Polysaccharide
Conjugate
Combination
Market segment by Application
Infant
Child
Aldult
Major players covered
AstraZeneca
Johnson & Johnson
Mylan N.V
Teva Pharmaceutical Industries Ltd
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Baxter
BIO-MED
Bio-Manguinhos
Walvax Biotechnology Co., Ltd
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Meningococcal Disease Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Meningococcal Disease Vaccine, with price, sales, revenue and global market share of Meningococcal Disease Vaccine from 2018 to 2023.
Chapter 3, the Meningococcal Disease Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Meningococcal Disease Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Meningococcal Disease Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Meningococcal Disease Vaccine.
Chapter 14 and 15, to describe Meningococcal Disease Vaccine sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Meningococcal Disease Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Meningococcal Disease Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Polysaccharide
1.3.3 Conjugate
1.3.4 Combination
1.4 Market Analysis by Application
1.4.1 Overview: Global Meningococcal Disease Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Infant
1.4.3 Child
1.4.4 Aldult
1.5 Global Meningococcal Disease Vaccine Market Size & Forecast
1.5.1 Global Meningococcal Disease Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Meningococcal Disease Vaccine Sales Quantity (2018-2029)
1.5.3 Global Meningococcal Disease Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Meningococcal Disease Vaccine Product and Services
2.1.4 AstraZeneca Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AstraZeneca Recent Developments/Updates
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Meningococcal Disease Vaccine Product and Services
2.2.4 Johnson & Johnson Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Johnson & Johnson Recent Developments/Updates
2.3 Mylan N.V
2.3.1 Mylan N.V Details
2.3.2 Mylan N.V Major Business
2.3.3 Mylan N.V Meningococcal Disease Vaccine Product and Services
2.3.4 Mylan N.V Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Mylan N.V Recent Developments/Updates
2.4 Teva Pharmaceutical Industries Ltd
2.4.1 Teva Pharmaceutical Industries Ltd Details
2.4.2 Teva Pharmaceutical Industries Ltd Major Business
2.4.3 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product and Services
2.4.4 Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
2.5 Pfizer Inc
2.5.1 Pfizer Inc Details
2.5.2 Pfizer Inc Major Business
2.5.3 Pfizer Inc Meningococcal Disease Vaccine Product and Services
2.5.4 Pfizer Inc Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Inc Recent Developments/Updates
2.6 GlaxoSmithKline plc
2.6.1 GlaxoSmithKline plc Details
2.6.2 GlaxoSmithKline plc Major Business
2.6.3 GlaxoSmithKline plc Meningococcal Disease Vaccine Product and Services
2.6.4 GlaxoSmithKline plc Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 GlaxoSmithKline plc Recent Developments/Updates
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Meningococcal Disease Vaccine Product and Services
2.7.4 Novartis AG Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis AG Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Meningococcal Disease Vaccine Product and Services
2.8.4 Sanofi Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sanofi Recent Developments/Updates
2.9 Merck & Co., Inc.
2.9.1 Merck & Co., Inc. Details
2.9.2 Merck & Co., Inc. Major Business
2.9.3 Merck & Co., Inc. Meningococcal Disease Vaccine Product and Services
2.9.4 Merck & Co., Inc. Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Merck & Co., Inc. Recent Developments/Updates
2.10 F. Hoffmann-La Roche Ltd
2.10.1 F. Hoffmann-La Roche Ltd Details
2.10.2 F. Hoffmann-La Roche Ltd Major Business
2.10.3 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product and Services
2.10.4 F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.11 Baxter
2.11.1 Baxter Details
2.11.2 Baxter Major Business
2.11.3 Baxter Meningococcal Disease Vaccine Product and Services
2.11.4 Baxter Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Baxter Recent Developments/Updates
2.12 BIO-MED
2.12.1 BIO-MED Details
2.12.2 BIO-MED Major Business
2.12.3 BIO-MED Meningococcal Disease Vaccine Product and Services
2.12.4 BIO-MED Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 BIO-MED Recent Developments/Updates
2.13 Bio-Manguinhos
2.13.1 Bio-Manguinhos Details
2.13.2 Bio-Manguinhos Major Business
2.13.3 Bio-Manguinhos Meningococcal Disease Vaccine Product and Services
2.13.4 Bio-Manguinhos Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bio-Manguinhos Recent Developments/Updates
2.14 Walvax Biotechnology Co., Ltd
2.14.1 Walvax Biotechnology Co., Ltd Details
2.14.2 Walvax Biotechnology Co., Ltd Major Business
2.14.3 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product and Services
2.14.4 Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Walvax Biotechnology Co., Ltd Recent Developments/Updates
3 Competitive Environment: Meningococcal Disease Vaccine by Manufacturer
3.1 Global Meningococcal Disease Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Meningococcal Disease Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Meningococcal Disease Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Meningococcal Disease Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Meningococcal Disease Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Meningococcal Disease Vaccine Manufacturer Market Share in 2022
3.5 Meningococcal Disease Vaccine Market: Overall Company Footprint Analysis
3.5.1 Meningococcal Disease Vaccine Market: Region Footprint
3.5.2 Meningococcal Disease Vaccine Market: Company Product Type Footprint
3.5.3 Meningococcal Disease Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Meningococcal Disease Vaccine Market Size by Region
4.1.1 Global Meningococcal Disease Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Meningococcal Disease Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Meningococcal Disease Vaccine Average Price by Region (2018-2029)
4.2 North America Meningococcal Disease Vaccine Consumption Value (2018-2029)
4.3 Europe Meningococcal Disease Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Meningococcal Disease Vaccine Consumption Value (2018-2029)
4.5 South America Meningococcal Disease Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Meningococcal Disease Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Meningococcal Disease Vaccine Consumption Value by Type (2018-2029)
5.3 Global Meningococcal Disease Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Meningococcal Disease Vaccine Consumption Value by Application (2018-2029)
6.3 Global Meningococcal Disease Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Meningococcal Disease Vaccine Market Size by Country
7.3.1 North America Meningococcal Disease Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Meningococcal Disease Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Meningococcal Disease Vaccine Market Size by Country
8.3.1 Europe Meningococcal Disease Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Meningococcal Disease Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Meningococcal Disease Vaccine Market Size by Region
9.3.1 Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Meningococcal Disease Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Meningococcal Disease Vaccine Market Size by Country
10.3.1 South America Meningococcal Disease Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Meningococcal Disease Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Meningococcal Disease Vaccine Market Size by Country
11.3.1 Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Meningococcal Disease Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Meningococcal Disease Vaccine Market Drivers
12.2 Meningococcal Disease Vaccine Market Restraints
12.3 Meningococcal Disease Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Meningococcal Disease Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Meningococcal Disease Vaccine
13.3 Meningococcal Disease Vaccine Production Process
13.4 Meningococcal Disease Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Meningococcal Disease Vaccine Typical Distributors
14.3 Meningococcal Disease Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Meningococcal Disease Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Meningococcal Disease Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 4. AstraZeneca Major Business
Table 5. AstraZeneca Meningococcal Disease Vaccine Product and Services
Table 6. AstraZeneca Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AstraZeneca Recent Developments/Updates
Table 8. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 9. Johnson & Johnson Major Business
Table 10. Johnson & Johnson Meningococcal Disease Vaccine Product and Services
Table 11. Johnson & Johnson Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Johnson & Johnson Recent Developments/Updates
Table 13. Mylan N.V Basic Information, Manufacturing Base and Competitors
Table 14. Mylan N.V Major Business
Table 15. Mylan N.V Meningococcal Disease Vaccine Product and Services
Table 16. Mylan N.V Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Mylan N.V Recent Developments/Updates
Table 18. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 19. Teva Pharmaceutical Industries Ltd Major Business
Table 20. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Product and Services
Table 21. Teva Pharmaceutical Industries Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 23. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Inc Major Business
Table 25. Pfizer Inc Meningococcal Disease Vaccine Product and Services
Table 26. Pfizer Inc Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Pfizer Inc Recent Developments/Updates
Table 28. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 29. GlaxoSmithKline plc Major Business
Table 30. GlaxoSmithKline plc Meningococcal Disease Vaccine Product and Services
Table 31. GlaxoSmithKline plc Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. GlaxoSmithKline plc Recent Developments/Updates
Table 33. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 34. Novartis AG Major Business
Table 35. Novartis AG Meningococcal Disease Vaccine Product and Services
Table 36. Novartis AG Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Novartis AG Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Meningococcal Disease Vaccine Product and Services
Table 41. Sanofi Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Sanofi Recent Developments/Updates
Table 43. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Merck & Co., Inc. Major Business
Table 45. Merck & Co., Inc. Meningococcal Disease Vaccine Product and Services
Table 46. Merck & Co., Inc. Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Merck & Co., Inc. Recent Developments/Updates
Table 48. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 49. F. Hoffmann-La Roche Ltd Major Business
Table 50. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Product and Services
Table 51. F. Hoffmann-La Roche Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 53. Baxter Basic Information, Manufacturing Base and Competitors
Table 54. Baxter Major Business
Table 55. Baxter Meningococcal Disease Vaccine Product and Services
Table 56. Baxter Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Baxter Recent Developments/Updates
Table 58. BIO-MED Basic Information, Manufacturing Base and Competitors
Table 59. BIO-MED Major Business
Table 60. BIO-MED Meningococcal Disease Vaccine Product and Services
Table 61. BIO-MED Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. BIO-MED Recent Developments/Updates
Table 63. Bio-Manguinhos Basic Information, Manufacturing Base and Competitors
Table 64. Bio-Manguinhos Major Business
Table 65. Bio-Manguinhos Meningococcal Disease Vaccine Product and Services
Table 66. Bio-Manguinhos Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Bio-Manguinhos Recent Developments/Updates
Table 68. Walvax Biotechnology Co., Ltd Basic Information, Manufacturing Base and Competitors
Table 69. Walvax Biotechnology Co., Ltd Major Business
Table 70. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Product and Services
Table 71. Walvax Biotechnology Co., Ltd Meningococcal Disease Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Walvax Biotechnology Co., Ltd Recent Developments/Updates
Table 73. Global Meningococcal Disease Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global Meningococcal Disease Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global Meningococcal Disease Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in Meningococcal Disease Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and Meningococcal Disease Vaccine Production Site of Key Manufacturer
Table 78. Meningococcal Disease Vaccine Market: Company Product Type Footprint
Table 79. Meningococcal Disease Vaccine Market: Company Product Application Footprint
Table 80. Meningococcal Disease Vaccine New Market Entrants and Barriers to Market Entry
Table 81. Meningococcal Disease Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global Meningococcal Disease Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global Meningococcal Disease Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global Meningococcal Disease Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global Meningococcal Disease Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global Meningococcal Disease Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global Meningococcal Disease Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global Meningococcal Disease Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global Meningococcal Disease Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global Meningococcal Disease Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global Meningococcal Disease Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global Meningococcal Disease Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global Meningococcal Disease Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global Meningococcal Disease Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global Meningococcal Disease Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America Meningococcal Disease Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America Meningococcal Disease Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America Meningococcal Disease Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America Meningococcal Disease Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe Meningococcal Disease Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe Meningococcal Disease Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe Meningococcal Disease Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Meningococcal Disease Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific Meningococcal Disease Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific Meningococcal Disease Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America Meningococcal Disease Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America Meningococcal Disease Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America Meningococcal Disease Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America Meningococcal Disease Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa Meningococcal Disease Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa Meningococcal Disease Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 140. Meningococcal Disease Vaccine Raw Material
Table 141. Key Manufacturers of Meningococcal Disease Vaccine Raw Materials
Table 142. Meningococcal Disease Vaccine Typical Distributors
Table 143. Meningococcal Disease Vaccine Typical Customers
List of Figures
Figure 1. Meningococcal Disease Vaccine Picture
Figure 2. Global Meningococcal Disease Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Meningococcal Disease Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Polysaccharide Examples
Figure 5. Conjugate Examples
Figure 6. Combination Examples
Figure 7. Global Meningococcal Disease Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Meningococcal Disease Vaccine Consumption Value Market Share by Application in 2022
Figure 9. Infant Examples
Figure 10. Child Examples
Figure 11. Aldult Examples
Figure 12. Global Meningococcal Disease Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Meningococcal Disease Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Meningococcal Disease Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Meningococcal Disease Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Meningococcal Disease Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Meningococcal Disease Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Meningococcal Disease Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Meningococcal Disease Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Meningococcal Disease Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Meningococcal Disease Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Meningococcal Disease Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Meningococcal Disease Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Meningococcal Disease Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Meningococcal Disease Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Meningococcal Disease Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Meningococcal Disease Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Meningococcal Disease Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Meningococcal Disease Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Meningococcal Disease Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Meningococcal Disease Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Meningococcal Disease Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Meningococcal Disease Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Meningococcal Disease Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Meningococcal Disease Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Meningococcal Disease Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Meningococcal Disease Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 54. China Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Meningococcal Disease Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Meningococcal Disease Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Meningococcal Disease Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Meningococcal Disease Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Meningococcal Disease Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Meningococcal Disease Vaccine Market Drivers
Figure 75. Meningococcal Disease Vaccine Market Restraints
Figure 76. Meningococcal Disease Vaccine Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Meningococcal Disease Vaccine in 2022
Figure 79. Manufacturing Process Analysis of Meningococcal Disease Vaccine
Figure 80. Meningococcal Disease Vaccine Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
